RAPS News: FDA/EMEA Common Application for Orphan Medicinal Products

| 01 February 2008

On 8 November 2007, the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) announced a Common Application for Orphan Medicinal Product Designation. The intent of the common application is to reduce the administrative burden on companies who wish to apply to orphan medicinal product designation in both the US and EU and thus, hopefully, to increase the number of products available to treat rare or "orphan" diseases in both jurisdictions.

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy